KRAS Drug Screening and Bioanalytical Technology Platform—From Recombinant Proteins to Cellular Functional Assays

The development of KRAS-targeted drugs relies on various biochemical and cellular-level analysis platforms. From the production and quality control of target proteins to the measurement of compound binding affinity with KRAS and the validation of signaling pathway inhibition in cells, a standardized analytical workflow is an indispensable infrastructure for drug discovery. This article focuses on the key technical modules in the KRAS drug screening system, including recombinant protein systems, in vitro biochemical assay models, and cellular efficacy evaluation systems.

High-quality recombinant KRAS protein is the starting point for inhibitor screening. KRAS is typically expressed in Escherichia coli systems and purified via affinity chromatography and size-exclusion chromatography to obtain high-purity, tag-free or appropriately tagged proteins. Since the nucleotide-loading state of KRAS directly affects its conformation and inhibitor binding, the production process requires loading it with GTP analogs (GppNHp, non-hydrolyzable form) or GDP to simulate active or inactive states. For mutants like G12C, the purification and storage process must prevent thiol oxidation to ensure cysteine remains in a reduced state.

A panel of mutant recombinant proteins is also essential for research and development. Suppliers provide KRAS proteins covering clinically common mutations such as G12C, G12D, G12V, G12R, G13D, and Q61H for selective evaluation and mutation-specific inhibitor screening. Quality control methods include SDS-PAGE, dynamic light scattering, mass spectrometry, and nucleotide exchange activity assays to ensure batch-to-batch consistency and functionality.

(1) TR-FRET Nucleotide Assay
This system uses a europium-labeled anti-GST antibody (donor) and an Alexa Fluor 647-labeled GDP (acceptor). When unlabeled GTP or inhibitors are added, they compete with fluorescent GDP for KRAS binding, leading to a reduction in FRET signal. By measuring the 665/620 nm fluorescence signal ratio, the IC50 of inhibitors can be calculated. This method is homogeneous, sensitive, and suitable for high-throughput screening.

(2) KRAS-Effector Binding Assay
TR-FRET or AlphaScreen technology is employed to mix biotinylated KRAS with labeled effector proteins (e.g., cRAF RBD). After adding inhibitors, the degree of disruption in protein-protein interactions is measured. This assay directly evaluates whether inhibitors can block KRAS binding to downstream signaling molecules, serving as a core indicator of functional activity.

(3) GTPase Activity Assay
Fluorescence-based phosphate release assays or mass spectrometry are used to quantitatively measure the GTP hydrolysis rate of KRAS itself, assessing whether compounds restore the impaired hydrolysis activity of mutants. Although GTPase restoration is an ideal mechanism, the primary function of most covalent inhibitors is irreversible binding to block effector interactions rather than restoring hydrolysis.

Compounds effective in vitro biochemical assays need validation for permeability and on-target effects in cellular models. Common cellular models include:

Engineered cell lines: Ba/F3 cell lines stably expressing different KRAS mutants (IL-3-dependent transformed to KRAS-dependent) are used to assess compound proliferation inhibition activity.

KRAS-mutant tumor cell lines: Examples include NCI-H358 (G12C), AsPC-1 (G12D), A549 (G12S), and SW480 (G12V). Proliferation inhibition is measured via CellTiter-Glo (ATP quantification) or MTT assays.

Signaling pathway assays: Western blotting is used to measure phosphorylation levels of downstream effector proteins like p-ERK, p-AKT, and p-S6, confirming the correlation between target inhibition and pathway shutdown.

Drug-resistant cell models are established to evaluate compound activity against secondary mutations. Resistance can be induced by prolonged low-concentration treatment or transfection with known resistance mutations (e.g., Y96D, R68S) for next-generation inhibitor screening.

In KRAS-deficient mouse embryonic fibroblast cells, recombinant expression of human KRAS mutants can construct ligand-dependent growth models. After compound addition, DNA synthesis inhibition is evaluated via BrdU incorporation or EdU staining. This model eliminates interference from endogenous KRAS, making it suitable for evaluating mutation-selective inhibitors.

Although preclinical in vivo models are not the focus of this article, KRAS drug development typically employs CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) models to evaluate efficacy. KRAS G12C inhibitors show dose-dependent tumor growth inhibition in NCI-H358 or MIA PaCa-2 models. Mouse PK/PD studies establish exposure-response relationships by measuring plasma drug concentrations and intratumoral p-ERK inhibition levels. Miniaturized bioanalytical tools (e.g., ELISA and MSD platforms) are also used to quantify tumor lysate occupancy rates of KRAS inhibitors.

Next-generation KRAS drug screening technologies are evolving toward higher throughput and multidimensional information. CRISPR-based gain/loss-of-function screens identify genes associated with inhibitor sensitivity. High-throughput live-cell imaging (high-content screening) enables simultaneous detection of proliferation, apoptosis, and KRAS signal localization at the single-cell level. Organoid platforms (3D cultures derived from patient tumors) are gradually replacing traditional 2D cell lines, offering efficacy evaluation systems closer to the in vivo microenvironment. These innovations will further shorten the path from hit compounds to preclinical candidates.

KRAS drug discovery relies on a comprehensive technical chain: from recombinant protein production and biochemical binding assays to cellular signal detection and functional evaluation. The precision and throughput of each step directly impact R&D efficiency and decision-making quality. With the integration of automation, miniaturization, and AI-assisted analysis, the KRAS drug screening platform will continue to evolve, providing a solid foundation for the development of more innovative molecules.